]>
IRCT20200111046084N1 IRCT 2020-05-15 Rajaie Cardiovascular Medical and Research Center Effect of rivaroxaban in radial artery thrombosis Efficacy and safety of rivaroxaban versus enoxaparin on treatment of radial artery thrombosis after coronary arteries angiography 2018-09-23 anticipated 40 Complete https://irct.ir/trial/45178 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be performed via permuted block randomization method. Allocation will be generated via a web based system and consequently concealment will be central using computer software. Unit of randomization will be individual patients and no stratification will be applied. 2 Radial artery thrombosis. Intervention 1: Intervention group: Rivaroxaban 20 mg oral tablet , patents will receive rivaroxaban 20 mg daily for 4 weeks after diagnosis of radial artery thrombosis. Intervention 2: Control group: Enoxaparin vial, 1 mg/kg subcutaneous daily for 4 weeks after diagnosis of radial artery thrombosis. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Parham Sadeghipour
Hashemi Rafsanjani highway; Vali-Asr street
Tehran Iran (Islamic Republic of) 1995614331 +98 21 2392 2092 psadeghipour@rhc.ac.ir Rajaie Cardiovascular Medical and Research Center scientific Parham Sadeghipour
Hashemi Rafsanjani highway; Vali-Asr street
Tehran Iran (Islamic Republic of) 1995614331 +98 21 2392 2092 psadeghipour@rhc.ac.ir Rajaie Cardiovascular Medical and Research Center Iran (Islamic Republic of) Provision of signed and dated informed consent form All the patients that diagnosed with radial artery thrombosis after coronary angiography Men and Women being at the age of 18 years old or over 18 years no limit Both Patients undergoing percutaneous coronary intervention A condition associated with a high risk of bleeding Severe renal dysfunction (creatinine clearance <30 mL/min) Being allergic to rivaroxaban/enoxaparin I74.2 Embolism and thrombosis of arteries of the upper extremities Treatment - Drugs Treatment - Drugs Intervention group: Rivaroxaban 20 mg oral tablet , patents will receive rivaroxaban 20 mg daily for 4 weeks after diagnosis of radial artery thrombosis Control group: Enoxaparin vial, 1 mg/kg subcutaneous daily for 4 weeks after diagnosis of radial artery thrombosis Radial artery recanalization. Timepoint: 4 weeks after start of treatment with rivaroxaban or enoxaparin. Method of measurement: Doppler Ultrasound. Bleeding. Timepoint: During 4 weeks of treatment with rivaroxaban or enoxaparin. Method of measurement: Questionnaire. Rajaie Cardiovascular Medical and Research Center Approved 2018-06-30 Ethic committee of Rajaie Cardiovascular Medical and Research Center Hashemi Rafsanjani highway; Vali-Asr street Tehran Tehran Iran (Islamic Republic of)